Fig. 3

MVP attenuated DOX-induced cardiac dysfunction in mice. A Validation of AAV9 overexpression efficiency in vivo. B Flow chart of the chronic DiCM models with the administration of AAV9. The heart function was examined 5 weeks after the AAV9 injection followed by euthanasia, and harvest tissues and serum for morphology analysis and biochemical examination. C Kaplan–Meier survival curve of mice exposed to repeated injections of both DOX (5 mg/kg, i.p., once a week, the total cumulative dose is 25 mg/kg) and AAV9 (n = 7 or 8). D, E of mice as determined via echocardiography 8 weeks from the first DOX injection (n = 6 or 7). EF, ejection fraction; FS, fractional shortening; LV Vol;s, left ventricular end-systolic volume; LV Vol;d, LV end-diastolic volume. F Activity of the MDA and the antioxidant enzyme SOD in the heart were detected. The data are shown as the fold change relative to the Con group. G The levels of LDH and CK-MB in serum 5 weeks after AAV9 injection. N = 6, values represent the mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001